CytomX Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics or view top-rated stocks.

Wall Street analysts have given CytomX Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CytomX Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

CytomX Therapeutics saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 3,640,000 shares, an increase of 20.9% from the January 14th total of 3,010,000 shares. Based on an average trading volume of 783,800 shares, the days-to-cover ratio is currently 4.6 days.
View CytomX Therapeutics' Short Interest.

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for CytomX Therapeutics.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Tuesday, February, 23rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.18. CytomX Therapeutics had a negative net margin of 58.13% and a negative trailing twelve-month return on equity of 94.20%.
View CytomX Therapeutics' earnings history.

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 42.1% and is now trading at $8.34.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12-month target prices for CytomX Therapeutics' stock. Their forecasts range from $8.50 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $11.75 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts' price targets for CytomX Therapeutics or view top-rated stocks among Wall Street analysts.

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Some companies that are related to CytomX Therapeutics include Ironwood Pharmaceuticals (IRWD), Olema Pharmaceuticals (OLMA), Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), Zealand Pharma A/S (ZEAL), DiaMedica Therapeutics (DMCAF), Y-mAbs Therapeutics (YMAB), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Praxis Precision Medicines (PRAX), MacroGenics (MGNX), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Phathom Pharmaceuticals (PHAT) and Arcturus Therapeutics (ARCT).
View all of CTMX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.23%), Victory Capital Management Inc. (5.01%), Renaissance Technologies LLC (4.47%), Nuveen Asset Management LLC (1.32%), Dimensional Fund Advisors LP (1.20%) and Northern Trust Corp (1.13%). Company insiders that own CytomX Therapeutics stock include Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends for CytomX Therapeutics.

CTMX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Panagora Asset Management Inc., Victory Capital Management Inc., Trexquant Investment LP, Congress Park Capital LLC, and Tudor Investment Corp Et Al.
View insider buying and selling activity for CytomX Therapeutics or view top insider-selling stocks.

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Barclays PLC, Assenagon Asset Management S.A., Squarepoint Ops LLC, Charles Schwab Investment Management Inc., Virginia Retirement Systems ET AL, Taddei Ludwig & Associates Inc., and XTX Markets LLC.
View insider buying and selling activity for CytomX Therapeutics or or view top insider-buying stocks.

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $8.34.

CytomX Therapeutics has a market capitalization of $385.51 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

CytomX Therapeutics employs 158 workers across the globe.

The official website for CytomX Therapeutics is www.cytomx.com.

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]